secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2024-09-26T23:59:59+00:00
Accession:  0001193125-24-227053
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences prices upsized $200M public offering of ordinary shares and pre-funded warrants
--------------------------------------------------------------------------------

- Offering of 23.1M ordinary shares at $8.00/share and 1.9M pre-funded warrants at $7.9999 each; gross proceeds ~$200M.
- Underwriters have 30-day option to purchase up to an additional 3.75M ordinary shares on same terms.
- Offering expected to close on or about Sept 27, 2024; cash runway extended into 2027 excluding GSK/Takeda milestones.
- Following close, pro forma ordinary shares outstanding expected to be approximately 148.4M.
- J.P. Morgan and Leerink Partners acting as joint book-running managers; Truist and Mizuho as book-runners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524227053/0001193125-24-227053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524227053/d817468d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-227053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer